Leukopenia and silver sulfadiazine

Area of Science:

• Pharmacology
• Dermatology
• Critical Care Medicine

Background:

• The association between silver sulfadiazine (SSD) treatment and leukopenia in burn patients has been debated.
• An increase in leukopenia incidence was observed in a burn unit starting in 1978.
• Leukopenia was primarily noted in patients receiving SSD, not other treatments.

Purpose of the Study:

• To investigate the potential relationship between silver sulfadiazine therapy and leukopenia.
• To explore a possible drug interaction between silver sulfadiazine and cimetidine, introduced concurrently.
• To assess the incidence of leukopenia in burn patients under different treatment regimens.

Main Methods:

• A prospective randomized study was conducted.
• Patients were treated with either silver sulfadiazine or other agents.
• The study compared leukopenia incidence between treatment groups, including those also receiving cimetidine.

Main Results:

• Leukopenia persisted in a significant percentage of patients across both treatment groups.
• The incidence of leukopenia was higher in patients treated with cimetidine compared to the control group.
• The study did not isolate silver sulfadiazine as the sole cause of leukopenia.

Conclusions:

• The introduction of cimetidine may have influenced the incidence of leukopenia in burn patients.
• A potential drug interaction between silver sulfadiazine and cimetidine warrants further investigation.
• The findings suggest that leukopenia in burn patients may be multifactorial, potentially involving drug interactions.